Your browser doesn't support javascript.
loading
Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism.
Wang, Chunlin; Zhang, Hui; Wang, Fu; Guo, Jun; Yuan, Jianlin; Hou, Guangdong; Gao, Ming; Li, Zheng; Zhang, Yan.
Afiliación
  • Wang C; Chair of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Zhang H; Chair of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Wang F; Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Guo J; Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Yuan J; Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Hou G; Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Gao M; Department of Andrology, Xi'an Daxing Hospital affiliated to Yan'an University, Xi'an, China.
  • Li Z; Shanghai Key Laboratory of Reproductive Medicine, Department of Andrology, Center for Men's Health, Urologic Medical Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhang Y; Department of Infertility and Sexual Medicine, 3rd Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Aging Male ; 27(1): 2288347, 2024 Dec.
Article en En | MEDLINE | ID: mdl-38146937
ABSTRACT

PURPOSE:

Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed. MATERIALS AND

METHODS:

A thorough examination of existing literature has been conducted on PubMed.

RESULTS:

PDE5i has good safety and efficacy, but the situation is more complex for patients with hypogonadism than those with normal testosterone levels, with reduced responsiveness to PDE5i. In this case, combination therapy with testosterone is recommended, safe and effective.

CONCLUSIONS:

Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Fosfodiesterasa 5 / Hipogonadismo / Disfunción Eréctil Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Aging Male Asunto de la revista: GERIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Fosfodiesterasa 5 / Hipogonadismo / Disfunción Eréctil Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Aging Male Asunto de la revista: GERIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido